Mind Medicine (MindMed) Inc. - Common Shares (MNMD)
12.91
+0.04 (0.31%)
NASDAQ · Last Trade: Oct 30th, 12:13 AM EDT
Detailed Quote
| Previous Close | 12.87 |
|---|---|
| Open | 13.02 |
| Bid | 12.66 |
| Ask | 12.73 |
| Day's Range | 12.70 - 13.65 |
| 52 Week Range | 4.700 - 14.30 |
| Volume | 1,695,345 |
| Market Cap | 498.27M |
| PE Ratio (TTM) | -8.383 |
| EPS (TTM) | -1.5 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,986,377 |
Chart
About Mind Medicine (MindMed) Inc. - Common Shares (MNMD)
Mind Medicine Inc. is a biotechnology company focused on developing innovative treatments for mental health disorders through the use of psychedelic medicine. The company is dedicated to advancing the scientific understanding of psychedelics and their potential therapeutic applications. By conducting rigorous clinical trials and research, Mind Medicine aims to create novel pharmaceutical products that can effectively address conditions such as anxiety, depression, and addiction. The organization's mission is to improve the quality of life for individuals suffering from mental health issues by harnessing the transformative power of psychedelics and providing evidence-based therapies. Read More
News & Press Releases
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 18,375,000 common shares, without par value, at a public offering price of $12.25 per common share. The gross proceeds to MindMed from the offering, before deducting underwriting discounts, commissions, and other offering-related expenses, are expected to be approximately $225 million. In addition, MindMed has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,756,250 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by MindMed.
By Mind Medicine (MindMed) Inc. · Via Business Wire · October 29, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. In addition, MindMed intends to grant the underwriters an option for a period of 30 days to purchase additional common shares at the public offering price, less underwriting discounts and commissions. All of the common shares and pre-funded warrants are being offered by MindMed.
By Mind Medicine (MindMed) Inc. · Via Business Wire · October 29, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to one newly hired non-executive employee consisting of an option to purchase 28,000 common shares of the Company (the "Option") with an effective grant date of October 14, 2025. The Option has an exercise price equal to the closing price of MindMed’s common shares on the date of the grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to the employee’s continued employment.
By Mind Medicine (MindMed) Inc. · Via Business Wire · October 14, 2025
Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid cash position.
Via Benzinga · October 13, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 182,800 common shares of the Company (the "Options") with effective grant dates of September 15, 2025 and September 22, 2025, depending on the applicable employee’s respective start date. The Options have an exercise price equal to the closing price of MindMed’s common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee’s continued employment.
By Mind Medicine Inc. · Via Business Wire · September 22, 2025
Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented results from a cross-sectional retrospective study of more than 75,000 respondents from the 2022 National Health and Wellness Survey at the Psych Congress 2025.
By Mind Medicine (MindMed) Inc. · Via Business Wire · September 19, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options to purchase an aggregate of 78,750 common shares of the Company (the "Options") with effective grant dates of August 25, 2025, September 2, 2025 and September 8, 2025, depending on the applicable employee’s respective start date. The Options have an exercise price equal to the closing price of MindMed’s common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee’s continued employment.
By Mind Medicine Inc. · Via Business Wire · September 8, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that JAMA has published full results from the Company’s positive Phase 2b study of MM120 (lysergide D-tartrate, LSD) in 198 adults with moderate-to-severe GAD. This is the first randomized, placebo-controlled trial to evaluate a single treatment across four dose levels (25, 50, 100, or 200 µg) as a monotherapy and did not include any form of study-related psychotherapeutic intervention. The study met its primary and key secondary endpoints, with MM120 demonstrating a dose-response relationship and significant symptom improvement versus placebo on the Hamilton Anxiety Rating Scale (HAM-A), a validated clinical tool used to assess the severity of anxiety.
By Mind Medicine Inc. · Via Business Wire · September 4, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:
By Mind Medicine Inc. · Via Business Wire · August 28, 2025
Mind Medicine stock hasn't beaten the market over the last five years, but what comes next?
Via The Motley Fool · August 12, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of (i) options to purchase an aggregate of 425,450 common shares of the Company (the "Options") and (ii) 34,500 performance share units (the “PSUs”) (assuming achievement at target levels of performance) that, if earned, will be settled in MindMed common shares upon vesting, with effective grant dates of July 25, 2025, August 4, 2025 and August 11, 2025, depending on the applicable employee’s respective start date. The Options have an exercise price equal to the closing price of MindMed’s common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee’s continued employment. The PSUs will vest on the third anniversary of the grant date, subject to continued service through the vesting date. Actual earned PSUs can range from 0%-200% of the target number of PSUs and will be based on the achievement of certain performance metrics as measured at the end of the three-year performance period.
By Mind Medicine Inc. · Via Business Wire · August 11, 2025
The U.S. public and the nation's politicians seem to be coming around to the idea of reforming psychedelic drug laws. Looser restrictions on research would help this company.
Via The Motley Fool · August 7, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its second quarter 2025 financial results and provided an update on business highlights.
By Mind Medicine Inc. · Via Business Wire · July 31, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30, 2025, and discuss recent business updates.
By Mind Medicine (MindMed) Inc. · Via Business Wire · July 24, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 96,400 common shares of the Company (the "Options"), with effective grant dates of July 7, 2025 and July 14, 2025, depending on the applicable employee’s respective start date. The Options have an exercise price equal to the closing price of MindMed’s common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee’s continued employment.
By Mind Medicine (MindMed) Inc. · Via Business Wire · July 14, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 128,750 common shares of the Company (the "Options"), with effective grant dates of June 2, 2025 and June 9, 2025, depending on the applicable employee’s respective start date. The Options have an exercise price equal to the closing price of MindMed’s common shares on the last trading day on which MindMed’s common shares traded prior to the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee’s continued employment.
By Mind Medicine Inc. · Via Business Wire · June 9, 2025
PALM BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Worldwide, there is a rising demand for neuropsychiatric disorder treatments which is expected to fuel the global markets for years to come. With expanding research and development efforts and a robust pipeline of novel medications, the neuropsychiatric disorders treatment landscape is evolving rapidly. Pharmaceutical companies are focusing on innovative drug therapies to meet the growing need for effective and affordable treatments. The market is primarily driven by the high incidence of mental illnesses, including depression and anxiety, and the rising awareness of these conditions. As a result, new treatment options are being developed, and drug-related activities such as clinical trials and drug approvals are intensifying. Recently an article on the 4th European Congress of Neurology and Neuropsychiatry website said that: “The global neuropsychiatric disorders and treatment market is on an upward trajectory, with a significant increase in demand for innovative solutions that cater to the growing burden of mental health conditions. In 2024, the market was valued at USD 130.5 billion, and by 2032, it is projected to reach USD 166.3 billion, growing at a compound annual growth rate (CAGR) of 10.20% from 2023 to 2032. This growth is fueled by continuous research, advancements in treatment, and heightened awareness of neuropsychiatric disorders.” Active Companies active today in markets include: Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Sage Therapeutics, Inc. (NASDAQ: SAGE), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), atai Life Sciences (NASDAQ: ATAI).
By FN Media Group LLC · Via GlobeNewswire · July 1, 2025
EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END
Via FinancialNewsMedia · July 1, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:
By Mind Medicine Inc. · Via Business Wire · May 28, 2025